Raymond James & Associates Ascendis Pharma A/S Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Raymond James & Associates holds 3,601 shares of ASND stock, worth $736,044. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,601

Previous 4,135 12.91%

Holding current value

$736,044

Previous $563,000 4.62%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$113.0 - $153.43 $60,342 - $81,931	-534 Reduced 12.91%	3,601 $537,000
Q2 2024 Jul 19, 2024	BUY	$121.07 - $153.67 $363 - $461	3 Added 0.07%	4,135 $563,000
Q1 2024 Apr 22, 2024	BUY	$123.45 - $159.4 $101,229 - $130,708	820 Added 24.76%	4,132 $624,000
Q4 2023 Jan 16, 2024	SELL	$86.1 - $127.36 $3,702 - $5,476	-43 Reduced 1.28%	3,312 $417,000
Q3 2023 Oct 24, 2023	SELL	$86.5 - $103.97 $15,310 - $18,402	-177 Reduced 5.01%	3,355 $314,000

Q2 2023 Jul 25, 2023	SELL	$69.96 - $97.84 $3,428 - $4,794	-49 Reduced 1.37%	3,532 $315,000
Q1 2023 Apr 14, 2023	BUY	$104.9 - $126.78 $12,588 - $15,213	120 Added 3.47%	3,581 $383,000
Q4 2022 Feb 08, 2023	SELL	$99.42 - $131.97 $101,308 - $134,477	-1,019 Reduced 22.75%	3,461 $422,000
Q3 2022 Oct 25, 2022	SELL	$84.03 - $110.23 $19,831 - $26,014	-236 Reduced 5.0%	4,480 $463,000
Q2 2022 Aug 12, 2022	SELL	$78.08 - $117.61 $17,021 - $25,638	-218 Reduced 4.42%	4,716 $438,000
Q1 2022 May 11, 2022	SELL	$102.18 - $135.75 $2.56 Million - $3.39 Million	-25,008 Reduced 83.52%	4,934 $579,000
Q4 2021 Feb 08, 2022	BUY	$127.1 - $169.66 $177,685 - $237,184	1,398 Added 4.9%	29,942 $4.03 Million
Q3 2021 Nov 02, 2021	BUY	$112.67 - $176.92 $288,097 - $452,384	2,557 Added 9.84%	28,544 $4.55 Million
Q2 2021 Aug 11, 2021	BUY	$121.62 - $145.29 $229,132 - $273,726	1,884 Added 7.82%	25,987 $3.42 Million
Q1 2021 May 14, 2021	BUY	$124.92 - $173.33 $367,514 - $509,936	2,942 Added 13.9%	24,103 $3.11 Million
Q4 2020 Feb 12, 2021	BUY	$151.2 - $182.76 $80,438 - $97,228	532 Added 2.58%	21,161 $3.53 Million
Q3 2020 Nov 04, 2020	BUY	$134.29 - $154.32 $2.56 Million - $2.94 Million	19,057 Added 1212.28%	20,629 $3.18 Million
Q2 2020 Jul 28, 2020	BUY	$110.87 - $156.01 $174,287 - $245,247	1,572 New	1,572 $232,000
Q1 2020 Apr 21, 2020	SELL	$97.01 - $145.11 $152,014 - $227,387	-1,567 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$91.45 - $139.12 $143,302 - $218,001	1,567 New	1,567 $218,000
Q2 2019 Aug 06, 2019	SELL	$107.11 - $132.09 $310,083 - $382,400	-2,895 Closed	0 $0
Q1 2019 May 06, 2019	BUY	$62.15 - $129.99 $179,924 - $376,321	2,895 New	2,895 $341,000

Others Institutions Holding ASND

# of Institutions

316

Shares Held

65.1M

Call Options Held

476K

Put Options Held

142K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $11.4B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Ascendis Pharma A/S Transaction History